Statins show promise for slowing macular degeneration in new trial
NCT ID NCT04735263
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether high-dose atorvastatin (a statin drug) can improve vision in people with intermediate age-related macular degeneration (AMD). Researchers will measure how quickly participants' eyes adjust to darkness and track changes in fatty deposits (drusen) in the retina. The goal is to see if dark adaptation can serve as an early sign of treatment success. The study involves 21 participants and is currently recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts Eye and Ear Infirmary
RECRUITINGBoston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a VR maze reveal hidden vision loss in macular degeneration?
- Can a new eye injection save vision in wet AMD?
- A new eye camera may spot stressed cells before vision loss begins
- A sharper look at the retina: new imaging technology may spot eye disease earlier
- Eye injection aims to tame leading causes of blindness
- Could light therapy help save sight in dry macular degeneration?